BioStem Technologies, Inc. (BSEM)
OTCMKTS · Delayed Price · Currency is USD
3.740
+0.040 (1.08%)
At close: Jun 24, 2026
BioStem Technologies Revenue
BioStem Technologies had revenue of $6.14M in the quarter ending March 31, 2026, a decrease of -91.54%. This brings the company's revenue in the last twelve months to $37.65M, down -88.67% year-over-year. In the year 2025, BioStem Technologies had annual revenue of $47.48M, down -84.27%.
Revenue (ttm)
37.65M
Revenue Growth
-88.67%
P/S Ratio
1.76
Revenue / Employee
1.14M
Employees
33
Market Cap
66.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 47.48M | -254.35M | -84.27% |
| Dec 31, 2024 | 301.83M | 285.14M | 1,708.93% |
| Dec 31, 2023 | 16.69M | 9.81M | 142.69% |
| Dec 31, 2022 | 6.88M | 2.53M | 58.38% |
| Dec 31, 2021 | 4.34M | 4.03M | 1,284.88% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 255.61M |
| Sangamo Therapeutics | 34.56M |
| Nuo Therapeutics | 4.13M |
| Arch Biopartners | 113.25K |
| Provectus Biopharmaceuticals | 57.48K |
BioStem Technologies News
- 7 days ago - BioStem Technologies Transcript: Planet MicroCap Las Vegas 2026 - Transcripts
- 7 days ago - BioStem Technologies Slides: FY 2026 - Filings
- 7 days ago - BioStem Technologies Slides: Company presentation - Filings
- 5 weeks ago - BioStem Technologies announces notice of allowance for four patents - TheFly
- 5 weeks ago - BioStem Technologies Transcript: 16th Annual LD Micro Invitational Conference - Transcripts
- 5 weeks ago - BioStem Technologies price target lowered to $7 from $9 at H.C. Wainwright - TheFly
- 5 weeks ago - BioStem Technologies Earnings Call Transcript: Q1 2026 - Transcripts
- 5 weeks ago - BioStem Technologies Earnings release: Q1 2026 - Filings